Oral vs. Injectable HMAs: Patient Perspectives, Access, and IRA Impact

EP: 1.Advances in MDS Classification and Molecular Understanding

EP: 2.Choosing MDS Therapies: Risk-Based Approaches

EP: 3.Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial

EP: 4.ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS

EP: 5.Oral vs. Injectable HMAs: Convenience and Efficacy in Higher Risk MDS

EP: 6.HMA Persistence and Effectiveness in Higher Risk MDS

EP: 7.Innovations and Future Directions in Higher Risk MDS Treatments

Now Viewing

EP: 8.Oral vs. Injectable HMAs: Patient Perspectives, Access, and IRA Impact

EP: 9.Oral vs. IV HMAs: Considerations and Patient Guidance

EP: 10.Patient Feedback for MDS: Insights and Closing Remarks

Video content above is prompted by the following:

• From a patient’s perspective, what are some of the advantages and disadvantages of using oral hypomethylating agents (HMAs) vs injectable HMAs?
• How do you anticipate the Inflation Reduction Act’s out-of-pocket prescription drug cost cap will affect access to oral HMAs starting in 2025?